FDA Approval Activities for this Drug
Prograf (tacrolimus capsules ,tacrolimus injection) Fujisawa Healthcare NDA 50-708/S10 12/1/00 5/2/03
Prograf (tacrolimus capsules ,tacrolimus injection) Fujisawa Healthcare NDA 50-708/S12 7/25/01 5/2/03
Prograf (tacrolimus capsules ,tacrolimus injection) Fujisawa Healthcare NDA 50-708/S13 12/1/00 5/2/03
Prograf (tacrolimus capsules, tacrolimus injection) Fujisawa Healthcare NDA 50-708/S15,S16 Protopic (Tacrolimus) Ointment, 0.03%/0.1%, Fujisawa Healthcare NDA 50-777/S4 4/18/03
Protopic (Tacrolimus) Ointment, 0.03%/0.1%, Fujisawa Healthcare NDA 50-777 Protopic (Tacrolimus) Ointment, Fujisawa Healthcare Prograf (tacrolimus) Capsules, Fujisawa Healthcare
Prograf (tacrolimus) Injection, Fujisawa Healthcare | PROTOPIC (tacrolimus) Ointment, Astellas Pharma, Package Change | Prograf (tacrolimus) Capsules, Astellas Pharma, Labeling Revision | Prograf (tacrolimus) Injection, Astellas Pharma, Labeling Revision | PROTOPIC (tacrolimus) Ointment, Astellas Pharma, Labeling Revision | Prograf (Tacrolimus) Capsules, Astellas Pharma, New or Modified Indication | Prograf (Tacrolimus) Injection, Astellas Pharma, New or Modified Indication | Prograf (tacrolimus) Capsules, Astellas Pharma, Labeling Revision | Prograf (tacrolimus) Injection, Astellas Pharma, Labeling Revision